State of the art: The hypereosinophilic syndromes
References (103)
Synthesis and secretion of eosinophil granule substances
Immunology Today
(1985)- et al.
Hemopoietins for eosinophils: Glycoprotein hormones that regulate the development of inflammation in eosinophilia-associated disease
Hematology/Oncology Clinics of North America
(1989) - et al.
Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GM-CSF
Blood
(1989) - et al.
Human eosinophil hematopoiesis studies in vitro by means of murine eosinophil differentiation factor (IL-5): Production of functionally active eosinophils from normal human bone marrow
Blood
(1988) - et al.
Effect of human recombinant interleukin 5 and G-CSF on eosinophil colony formation
Immunology Letters
(1988) - et al.
Peripheral blood myeloid progenitor cell cultures in patients with hypereosinophilic syndrome (CFU-Eos in hypereosinophilic syndrome)
Blood
(1982) - et al.
In vivo administration of antibody to interleukin-5 inhibits increased generation of eosinophils and their progenitors in bone marrow of parasitized mice
Blood
(1990) - et al.
T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation
Blood
(1989) - et al.
The appearance of hypodense eosinophils during interleukin-2 treatment
Journal of Allergy and Clinical Immunology
(1990) - et al.
Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients
Blood
(1987)
Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemia with a Del (5q)
Blood
(1989)
A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations
Blood
(1981)
Eosinophilic meningitis and the hypereosinophilic syndrome. Case report and review of the literature
American Journal of Medicine
(1985)
Trisomy 22—A new abnormality found in acute leukemia characterized by eosinophilia and monocytoid blasts expressing immature differentiation antigens
Cancer Genetics and Cytogenetics
(1986)
Acute eosinophilic leukemia with a translocation (10p+;11q−)
Cancer Genetics and Cytogenetics
(1986)
Current concepts. Eosinophil function
New England Journal of Medicine
(1981)
A case of the eosinophilia-myalgia syndrome associated with use of an L-tryptophan product
Annals of Internal Medicine
(1990)
Eosinophilopoiesis
Eosinophils: morphology, production, chemistry and function
Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium
Journal of Experimental Medicine
(1985)
Platelet activating factor: A potent chemotactic and chemokinetics factor for human eosinophils
Journal of Clinical Investigation
(1986)
Recombinant human interleukin 5 is a selective eosinophil chemoattractant
European Journal of Immunology
(1989)
Characterization of a factor produced by human T-cell clones exhibiting eosinophil-activating and burst-promoting activities
Journal of Immunology
(1987)
Humoral regulation of eosinophilopoiesis in vitro: analysis of the targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin 5
Leukemia
(1989)
Synergism among interleukin 1, interleukin 3, and interleukin 5 in the production of eosinophils from primitive hemopoietic stem cells
Journal of Immunology
(1988)
Functions of the eosinophil leukocyte
British Journal of Haematology
(1976)
The hypereosinophilic syndrome: analysis of 14 cases with review of the literature
Medicine
(1975)
Altered density, metabolism, and surface receptors of eosinophils in eosinophilia
Immunology
(1982)
Fegamma and receptor expression on normal density and low density human eosinophils
Immunology
(1990)
Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia
New England Journal of Medicine
(1980)
Heterogeneity of human peripheral blood eosinophils: Variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophila
International Archives of Allergy and Applied Immunology
(1983)
Hypereosinophilic syndrome human eosinophil degranulation induced by soluble and particulate stimuli
British Journal of Haematology
(1988)
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony stimulating factor
Journal of Immunology
(1986)
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts
Journal of Experimental Medicine
(1987)
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3
Journal of Clinical Investigation
(1988)
Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor
Journal of Experimental Medicine
(1988)
Recombinant human interleukin 5 is a selective activator of human eosinophil function
Journal of Experimental Medicine
(1988)
Stimulation of eosinophil adherence to human vascular endothelial cells in vitro by platelet-activating factor
Journal of Immunology
(1988)
Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor
Journal of Cellular Biochemistry
(1988)
Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome
Journal of Experimental Medicine
(1989)
Mechanism of eosinophilia II. Role of the lymphocyte
Journal of Experimental Medicine
(1970)
Mature human eosinophils have the capacity to express HLA-DR
Specific production of eosinophil colony stimulating factor from sensitized T-cells from a patient with allergic eosinophilia
British Journal of Haematology
(1985)
Interleukin 2 stimulates the T cells from patients with eosinophilia to produce CFU-Eo growth stimulating factor
British Journal of Haematology
(1988)
T lymphocyte control of human eosinophilic granulopoiesis
Journal of Immunology
(1987)
Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells
J Immunol
(1989)
Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution
Blut
(1986)
Interleukin-2-dependent release of interleukin-3 activity by T4+ human T-cell clones
Role of IL-5 in IL-2 induced eosinophilia: in vivo and in vitro expression of IL-5 mRNA by IL-2
Journal of Immunology
(1990)
The biological role of interleukin 5
International Journal of Cell Cloning
(1990)
Cited by (33)
Blood eosinophilia: A new paradigm in disease classification, diagnosis, and treatment
2005, Mayo Clinic ProceedingsCitation Excerpt :For now, HES is considered a subcategory of idiopathic eosinophilia that requires documentation of both target organ damage and an AEC of 1500 cells/µL or greater for at least 6 months.20,86 Several review articles have described the clinical manifestations and natural history of HES.20,86–88 These and other case reports have shown that some cases evolve into either acute leukemia or an aggressive disease phenotype that is indistinguishable from an MPD.89–91
The role of thymus-dependent T cells in hexachlorobenzene-induced inflammatory skin and lung lesions
1999, Toxicology and Applied PharmacologyEosinophilia in aids
1997, Immunology and Allergy Clinics of North AmericaCough, shortness of breath, and eosinophilia in a 68-year-old man
1996, Annals of Allergy, Asthma and ImmunologyThe first report of idiopathic hypereosinophilic syndrome involved with lung and middle ear
1995, American Journal of the Medical SciencesThe idiopathic hypereosinophilic syndrome
1994, Blood
Copyright © 1991 Published by Elsevier Ltd.